Chronic fatigue immune dysfunction syndrome: Neuroendocrine alterations;Kronik yorgunluk i̇mmün disfonksiyon sendromu: Nöroendokrin deǧişiklikler

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 2, 2006, Pages 133-146

  Izgi, Hasan Basri ^a   Sofuoǧlu, Seher ^a   Asdemir, Akif ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Adrenal gland; Adrenal steroids; Chronic fatigue immune dysfunction syndrome; Hypothalamo pituitary adrenal axis; Neuroendocrine; Serotonin

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PRASTERONE; TRANSCORTIN;

CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; COMORBIDITY; ENDOCRINE FUNCTION; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOPATHOLOGY; NEUROENDOCRINE SYSTEM; REVIEW; SEROTONINERGIC SYSTEM;

EID: 33745882365     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Cleare AJ. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004; 15: 55-59
2. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003; 24: 236-252
3. Taylor RR, Jason LA, Richman JA, Torres Harding SR, King C, Song S. Epidemiology. In Handbook of Chronic Fatigue Syndrome. Jason LA, Fennell PA, Taylor RR (editors). John Wiley & Sons, Inc. New Jersey 2003:3-26
4. Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-959
5. Wessely S, Hotopf M, Sharpe M. Chronic Fatigue and its Syndromes. Oxford University Press, 1998 pp: 173, 475-481
6. Tattersall R. Hypoadrenia or "a bit of Addison's disease". Med Hist 1999; 43: 450-457
7. Leese G, Chattington P, Fraser W, Vora J, Edwards R, Williams G. Short-term night shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome. J Clin Endocrinol Met 1996; 81:1867-1870
8. Brosnan CM, Cowing NFC. Addison's disease. BMJ 1996; 312: 1085-1087
9. Avgerinos PC, Chrousos GP, Nieman LK, Oldfield EH, Loriaux DL, Cutler BG. The CRH test in the postoperative evaluation of patients with Cushing's syndrome. J Clin Endocrinol Metab 1987; 65: 906-913
10. Riordain D, Farley D, Young W, Grant C, van Heerden J. Long term outcome of bilateral adrenalectomy in patients with Cushing's syndrome. Surgery 1994; 116: 1088-1093
11. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73: 1224-1234
12. Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 35: 239-283
13. Yatham L, Morehouse R, Chisholm B, Haase D, MacDonald D, Marrie T. Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome. Can J Psychiatry 1995; 40: 93-96
14. Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 1997; 22: 261-267
15. Scott L, Dinan T. Neuro-endocrine abnormalities in chronic fatigue syndrome: focus on the stress axis. Balliere's Clinical Psychiatry 1999; 3: 419-432
16. Gaab J, Huster D, Peisen R. Hypothalamus-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom Med 2002; 64: 951-962
17. Young AH, Sharpe M, Clements A, Dowling B, Hawton KE, Cowen PJ. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biol Psychiatry 1998; 43: 236-237
18. Scott L, Dinan T. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 1998; 47: 49-54
19. Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry 2001; 158: 641-643
20. Thompson LM, Rubin RT, McCracken JT. Neuroendocrine aspects of primary endogenous depression: XII Receiver operating characteristics and kappa analyses of serum and urine cortisol measure in patients and matched controls. Psychoneuroendocrinology 1992; 17: 507-515
21. MacHale SM, Cavanagh JT, Bennie J, Carroll S, Goodwin GM, Lawrie SM. Diurnal variation of adrenocortical activity in chronic fatigue syndrome. Neuropsychobiology 1998; 38: 213-217
22. Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS. Hypothalamo-pituitary-adrenal axis function in chronic fatigue syndrome and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001; 86: 3545-3554
23. Antoni F. Vasopressinergic control of pituitary adrenocorticotrophin secretion comes of age. Front Neuroendocrinol 1993; 14: 76-122
24. DeBold CR, Sheldon WR, DeCherney GS, Jackson RV, Alexander AN, Vale W. Arginine vasopressin potentiates adrenocorticotrophin release induced by corticotrophin releasing factor. J Clin Invest 1984; 73: 533-538
25. Altemus M, Dale JK, Michelson D, Demitrack MA, Gold PW, Straus SE. Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. Psychoneuroendocrinology 2001; 26: 175-188
26. Bakheit AM, Behan PO, Watson WS, Morton JJ. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol Scand 1993; 87: 234-238
27. Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999; 45:1447-1454
28. Kirnap M, Çolak R, Eser C, Özsoy O, Tutuş A, Keleştimur F. A comparison between low-dose (1μg), standart dose (250 μg) ACTH stimulation tests and insulin tolerance test in evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol 2001; 55: 455-459
29. Hudson M, Cleare AJ. The 1 microg short synacthen test in chronic fatigue syndrome. Clin Endocrinol 1999; 51: 625-630
30. Scott LV, Medbak S, Dinan TG. The low dose adrenocorticotropin test in chronic fatigue syndrome and in health. Clin Endocrinol 1998; 48: 733-737
31. Cleare AJ. Neuroendocrine dsyfunction. In Handbook of Chronic Fatigue Syndrome, Jason LA, Fennell PA, Taylor RR (editors), New Jersey: John Wiley &Sons, 2003: 331-360
32. İzgi HB, Gökçe C, Çaliş M, Turan T, Kirnap M, Sofuoǧlu S, Durak AC, Tutuş A, Keleştimur F. Investigation of the hypothalamopituitary-adrenal axis by low-dose (1μg) adrenocorticotropic hormone test and metyrapone test in patients with chronic fatigue syndrome. Endocrinologist 2005; 15: 89-92
33. Çaliş M, Gökçe C, Ateş F, Ülker S, İzgi HB, Demir H, Kirnap M, Sofuoǧlu S, Durak AC, Tutuş A, Keleştimur F. Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1μg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004; 27: 42-46
34. Ottenweller JE, Sisto SA, McCarty RC, Natelson BH. Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology 2001; 43: 34-41
35. Eşel E. Depresyondaki nöroendokrinolojik bulgular. Klinik Psikiyatri Dergisi 2002; 4: 35-50
36. Yehuda R, Boisoneau D, Lowy MT, Giller EL. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. Arch Gen Psychiatry 1995; 52: 583-93
37. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000; 25: 1-35
38. Poland RE, Lin KM, Lutchmansingh P, McCracken JP. Biological markers in CFIDS and neurasthenia. X World Congress of Psychiatry, 1996, Madrid, Spain
39. Lavelle E, Dinan TG. Hypothalamo-pituitary-adrenal axis function in chronic fatigue syndrome: a study of fast feedback mechanisms. Royal College of Surgeons of Ireland Research Meeting, 1996, Dublin
40. Gaab J, Huster D, Peisen R. The low dose dexamethasone suppression test in chronic fatigue syndrome and health. Psychosom Med 2002; 64: 311-318
41. Pruessner JC, Hellhammer DH, Kirschbaum C. Burnout, perceived stress, and cortisol responses to awakening. Psychosom Med 1999; 61: 197-204
42. Goenjian AK, Yehuda R, Pynoos RS, Steinberg AM, Tashjian M, Yang RK. Basal cortisol, dexamethasone suppression of cortisol, and MHPG in adolescents after the 1988 earthquake in Armenia. Am J Psychiatry 1996; 153: 929-934
43. Stein MB, Yehuda R, Koverola C, Hanna C. Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse. Biol Psychiatry 1997; 42: 680-686
44. Visser J, Blauw B, Hinloopen B, Brommer E, de Kloet ER, Kluft C. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis 1998; 177: 451-454
45. Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry 2001; 158: 641-643
46. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocrine abstracs 2003;5:S35
47. Harvey A, Purdie G, Bushnell J, Ellis P. Are cortisol levels low in chronic fatigue syndrome? A meta-analysis. AHMF conference. Third International Clinical and Scientific Meeting on ME/CFIDS, 2001, Sydney, Australia
48. Parker AJR, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001; 31: 1331-1345
49. Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotrophin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998; 97: 450-457
50. Cleare AJ, Wessely SC. Chronic fatigue syndrome: a stress disorder? Br J Hosp Med 1996; 55: 571-574
51. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286: 1360-1368
52. Cleare AJ. Preliminary data presented at British Association for Psychopharmacology Summer Meeting, 2000, Cambridge, UK
53. Scott LV, Svec F, Dinan T. A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. Psychiatry Res 2000; 97: 21-28
54. Baulieu EE. Dehydroepiandrostenedione (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996; 81: 3147-3151
55. Eşel E, Kartalci Ş, Tutuş A, Turan T, Sofuoǧlu S. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 303-309
56. Barret-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999; 47: 685-691
57. Kuratsune H, Yamaguti K, Sawada M, Kodate S, Machii T, Kanakura Y, Kitani T. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med 1998; 1:143-146
58. De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999; 31:18-21
59. Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG. Differences in adrenal steroid profile in chronic fatigue syndrome in depression and in health. J Affect Disord 1999; 54:129-137
60. Cleare AJ, O'Keane V, Miell JP. Levels of DHEA and DHEAS and response to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology 2004; 29: 724-732
61. İzgi HB. Kronik Yorgunluk Sendromunda Galantamin Tedavisinin Kortizol ve DHEAS Düzeyleri Üzerine Etkileri. Yayinlanmamiş Uzmanlik Tezi, Erciyes Üniversitesi Tip Fakültesi, Psikiyatri anabilim dali., Kayseri: 2005
62. Arlt W, Beuschlein F, Allolio B. Adrenal cortex insufficiency: diagnosis and therapy. Med Klin 1999; 94: 353-354
63. Wallymahmed ME, Foy P, MacFarlane IA. The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects. Clin Endocrinol 1999; 51: 333-338
64. Allain TJ, Bearn JA, Coskeran P, Jones J, Checkley A, Butler J. Changes in growth hormone, insulin, insulin-like growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997; 41: 567-573
65. Cleare AJ, Sookdeo SS, Jones J, O'Keane V, Miell JP. Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 2000; 85: 1433-1439
66. Moorkens G, Berwaerts J, Wynants H, Abs R. Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome. Clin Endocrinol 2000; 53: 99-106
67. İzgi HB, Özsoy S, Tanriverdi F, Baştürk M, Turan T, Keleştimur F, Eşel E, Kirnap M, Sofuoǧlu S. Effect of low-dose hydrocortisone treatment on insulin-like growth factor-1 in female patients with chronic fatigue syndrome. Report presented at ECNP, 2005, Amsterdam, Holland
68. Cleare AJ, Sookdeo SS, Jones J, O'Keane V, Miell JP. Plasma leptin in chronic fatigue syndrome, and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion. Clin Endocrinol 2001; 55: 113-119
69. Korszun A, Sackett-Lundeen L, Papadopoulos E, Brucksch C, Masterson L, Engelberg NC. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999; 26: 2675-2680
70. Sofuoǧlu S, Eşel E, İzgi HB, Baştürk M, Keleştimur F, Kirnap M, Turan T. Serum TSH and PRL levels in patients with chronic fatigue syndrome: compared to depressed patients. Report presented at 3rd Regional Congress of ISPNE (International Society of Psychoneuroendocrinology), 2004, Nevşehir, Turkey
71. İzgi HB, Özsoy S, Tanriverdi F, Baştürk M, Turan T, Keleştimur F, Eşel E, Kirnap M, Sofuoǧlu S. Effect of low-dose hydrocortisone treatment on serum TSH and PRL levels in female patients with chronic fatigue syndrome. Report presented at ECNP, 2005, Amsterdam, Holland
72. Hamilos DL, Nutter D, Gershtenson J, Ikle DI, Hamilos SS, Redmond DP. Circadian rhythm of core body temperature in subjects with chronic fatigue syndrome. Clin Physiol 2001; 21: 184-195
73. Papadopoulos E, Crofford LJ, Engleberg NC, Korszun A, Brucksch C, Eisner S. Impaired HPA axis activity in chronic fatigue syndrome and fibromyalgia. Biol Psychiatry 1997; 41 (Suppl.1): 29
74. Demitrack M, Crofford L. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998; 840: 684-697
75. Wood B, Wessely S, Papadopoulos A, Poon L, Checkley S. Salivary cortisol profiles in chronic fatigue syndrome. Neuropsychobiology 1998; 37: 1-4
76. Williams G, Pirohamed J, Minors D, Waterhouse J, Buchan I, Arendt J. Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome. Clin Physiol 1996; 16: 327-337
77. Scott LV, Teh J, Reznek R, Martin A, Sohaib A, Dinan TG. Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. Psychoneuroendocrinology 1999; 24: 759-768
78. Brooks J, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol 2000; 73: 1206-1208
79. McEwen BS, Magarinos AM. Stress effects on morphology and function of the hippocampus. Ann N Y Acad Sci 1997; 821: 271-284
80. McAllister-Williams RH, Ferrier IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med 1998; 28: 573-584
81. Dinan TG. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 1994; 164: 365-371
82. Checkley SA. Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med 1980; 10: 35-53
83. Bakheit A, Behan P, Dinan T, Gray C, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992; 304: 1010-1012
84. Meltzer HGG, Lowy M, Nash J, Koening J. Effects of buspirone: mediation by dopaminergic and serotonergic mechanisms. In Buspirone: Mechanisms and Clinical Aspects. Tunnicliff G, Eison AS, Taylor OP (editors), San Diego, CA: Academic Press, 1991: 177-192
85. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and 11C WAY-100635. Biol Psychiatry 2005; 57: 239-246
86. Taylor T, Dluhy R, Williams G. Beta-endorphin suppresses adrenocorticotrophin and cortisol levels in normal human subjects. J Clin Endocrinol Metab 1983; 57: 592-596
87. Dinan TG. Psychoneuroendocrinology of depression: growth hormone. Psychiatr Clin North Am. 1998; 21: 325-339
88. Conti F, Pittoni V, Sacerdote P, Priori R, Meroni PL, Valesini G. Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol 1998; 16: 729-732
89. Terenius L, Wahlstrom A. Physiological and clinical relevance or endorphins. In Hughes J (editor). Centrally Acting Peptides. Baltimore: University Park Press, 1978: 161-178
90. Demitrack M, Gold P, Dale J, Krahan D, Kling M, Straus S. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry 1992; 32: 1065-1077
91. Odagiri Y, Shimomitsu T, Iwane H, Katsumura T. Relationships between exhaustive mood state and changes in stress hormones following an ultraendurance race. Int J Sports Med 1996; 17: 325-331
92. Chaudhuri A, Majeed T, Dinan T, Behan PO. Chronic fatigue syndrome: a disorder of central cholinergic neurotransmission. Journal of Chronic Fatigue Syndrome 1997; 3: 3-16
93. Torpy DJ, Bachmann AW, Grice JE, Fitzgerald SP, Phillips PJ, Whitworth JA. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001; 86: 3692-3700
94. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M. Low-dose hydrocortisone treatment of chronic fatigue syndrome: results of a placebo-controlled study of its efficacy and safety. JAMA 1998; 280: 1061-1066
95. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Lowdose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999; 353: 455-458
96. Himmel P, Seligman T. A pilot study employing dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome. J Clin Rheumatol 1999; 5: 56-59
97. Baschetti R. Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome. J Clin Endocrinol Metab 1999; 84: 2263-2264
98. Bou-Holaigah I, Rowe P, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274: 961-967
99. Peterson PK, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998; 158: 908-914
100. Moorkens G, Wynants H, Abs R. Effect of growth hormone treatment in patients with chronic fatigue syndrome: a preliminary study. Growth Horm IGF Res 1998; 8:131-133